Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
June 02, 2024 10:00 ET
|
Precede Biosciences, Inc.
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancersER status was accurately assessed and the level of ER pathway activation quantified in 87...
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024 17:55 ET
|
Myriad Genetics, Inc.
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved...
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 08, 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study...
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
April 25, 2024 05:00 ET
|
PEP-Therapy
Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patientsdans la phase Ib de l’essai clinique évaluant PEP-010dans les cancers de l’ovaire et du pancréas ...
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
April 25, 2024 05:00 ET
|
PEP-Therapy
Press release PEP-Therapy and Institut Curie Announce First Patients Dosedin Phase Ib Clinical Trial Evaluating PEP-010in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy,...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 11, 2024 11:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
April 10, 2024 08:21 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
April 08, 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update